Johnson & Johnson gets FDA approval for schizophrenia drug

12/8/2003 | NYTimes.com

Drugmaker Johnson & Johnson announced it has received FDA approval for its schizophrenia drug, Risperdal, to treat bipolar I disorder, the most severe form of the disease. The company said users of the drug showed significant improvement over persons treated in a control group.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Financial Officer
B. E. Smith
Miramar, FL
Food Lawyer
Cargill
Wayzata, MN
Claims Director
PacificSource
Springfield, OR